The FDA called for stronger warnings on the labels of Remicade, Humira, Enbrel and Cimzia to inform patients about the risk of developing histoplasmosis, a harmful fungal infection. The drugs, also known as tumor necrosis factor blockers, are approved in the U.S. for treating rheumatoid arthritis and Crohn's disease.

Related Summaries